Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2026)

Crinetics Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 249273000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 357.58% year-over-year to 249273000.0 in Q1 2026; TTM through Mar 2026 was 386362000.0, a 2982.01% decrease from a year earlier, with the FY2025 full-year figure at 465317000.0, down 56.18% from the prior year.
• Income from Continuing Operations declined to 249273000.0 in Q1 2026 per CRNX's latest filing, from 122635000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 115637000.0 in Q2 2025 and bottomed at 362766000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 42375000.0 (2022), against an average of 20759941.18.
• Across the five-year window, Income from Continuing Operations soared 124.39% in 2022 and tumbled 906.31% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 44991000.0 in 2022, then tumbled by 906.31% to 362766000.0 in 2023, then jumped by 77.78% to 80595000.0 in 2024, then tumbled by 52.16% to 122635000.0 in 2025, then plunged by 103.26% to 249273000.0 in 2026.
• Per Business Quant, the three latest CRNX Income from Continuing Operations figures stand at 249273000.0 (Q1 2026), 122635000.0 (Q4 2025), and 130091000.0 (Q3 2025).